within Pharmacolibrary.Drugs.ATC.A;

model A06AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.004166666666666667,
    adminDuration  = 600,
    adminMass      = 24 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lubiprostone is a chloride channel activator used for the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation (IBS-C) in adults. It is approved by regulatory agencies such as the FDA and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics of lubiprostone after oral administration in healthy adult volunteers as referenced in the published literature.</p><h4>References</h4><ol><li><p>McKeage, K, et al., &amp; Siddiqui, MA (2006). Lubiprostone. <i>Drugs</i> 66(6) 873–879. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200666060-00015&quot;>10.2165/00003495-200666060-00015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16706562/&quot;>https://pubmed.ncbi.nlm.nih.gov/16706562</a></p></li><li><p>Rivkin, A, &amp; Chagan, L (2006). Lubiprostone: chloride channel activator for chronic constipation. <i>Clinical therapeutics</i> 28(12) 2008–2021. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2006.12.013&quot;>10.1016/j.clinthera.2006.12.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17296458/&quot;>https://pubmed.ncbi.nlm.nih.gov/17296458</a></p></li><li><p>Johanson, JF, &amp; Ueno, R (2007). Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. <i>Alimentary pharmacology &amp; therapeutics</i> 25(11) 1351–1361. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2036.2007.03320.x&quot;>10.1111/j.1365-2036.2007.03320.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17509103/&quot;>https://pubmed.ncbi.nlm.nih.gov/17509103</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AX03;
